Skip to main content

Table 9 Plasma miRNA results in MD patients with normal vs. impaired systolic function

From: Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

miRNA plasma levelsa (/103) Normal LV and RV function Impaired LV and/or RV function p value
N = 31 N = 32
-206 31.77 (4.83–79.62) 11.27(3.52–50.27) 0.58
-144-5p 33.14 (0.00–525.08) 0.00 (0.00–98.72) 0.29
-146b 74.79 (0.00–173.85) 29.92 (0.00–177.79) 0.60
-15b 0.00 (0.00–18.15) 0.18 (0.00–21.81) 0.77
-195 9.01 (0.35–18.62) 8.93 (1.90–22.0) 0.66
-20b 53.99 (25.84–83.60) 65.45 (19.35–87.12) 0.66
-21 42.09 (0.00–102.71) 13.65 (0.00–150.01) 0.41
-221 0.00 (0.00–18.27) 0.00 (0.00–18.55) 0.36
-222 1801.09 (1215.81–3491.60) 2006.29 (638.43–6059.36) 0.79
-26a 283.14 (110.62–512.14) 362.31 (121.25–622.72) 0.36
-29a 0.00 (0.00–0.00) 0.00 (0.00–0.05) 0.39
-29c 0.00 (0.00–0.47) 0.00 (0.00–2.16) 0.27
-342 2249.28 (1294.10–3353.27) 2570.15 (888.62–5565.11) 0.54
-378a-3p 28.84 (6.04–155.98) 32.92 (1.76–301.61) 0.98
-378a-5p 27.57 (12.50–56.49) 26.02 (7.00–84.56) 0.78
−451 184.13 (100.07–349.44) 171.93 (22.68–307.38) 0.77
−93 26.19 (0.00–70.81) 27.17 (0.00–53.75) 0.81
  1. (a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 103 in order to increase readability
  2. Bold text indicates a significant p-value of <0.05